These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 32788835)

  • 1. COVID-19: Clinical aspects and therapeutics responses.
    Khan S; Ali A; Shi H; Siddique R; Shabana ; Nabi G; Hu J; Wang T; Dong M; Zaman W; Han G
    Saudi Pharm J; 2020 Aug; 28(8):1004-1008. PubMed ID: 32788835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Early Combination Therapy With Lianhuaqingwen and Arbidol in Moderate and Severe COVID-19 Patients: A Retrospective Cohort Study.
    Fang J; Li H; Du W; Yu P; Guan YY; Ma SY; Liu D; Chen W; Shi GC; Bian XL
    Front Pharmacol; 2020; 11():560209. PubMed ID: 33071781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
    Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
    Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of nelfinavir in asymptomatic and mild COVID-19 patients: a structured summary of a study protocol for a multicenter, randomized controlled trial.
    Hosogaya N; Miyazaki T; Fukushige Y; Takemori S; Morimoto S; Yamamoto H; Hori M; Kurokawa T; Kawasaki Y; Hanawa M; Fujii Y; Hanaoka H; Iwami S; Watashi K; Yamagoe S; Miyazaki Y; Wakita T; Izumikawa K; Yanagihara K; Mukae H; Kohno S;
    Trials; 2021 Apr; 22(1):309. PubMed ID: 33910617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidemiological and clinical characteristics of coronavirus disease (COVID-19) cases at a screening clinic during the early outbreak period: a single-centre study.
    Khan M; Khan H; Khan S; Nawaz M
    J Med Microbiol; 2020 Aug; 69(8):1114-1123. PubMed ID: 32783802
    [No Abstract]   [Full Text] [Related]  

  • 6. Characteristics, Treatment Outcomes and Role of Hydroxychloroquine among 522 COVID-19 hospitalized patients in Jaipur City: An Epidemio-Clinical Study.
    Bhandari S; Singh A; Sharma R; Rankawat G; Banerjee S; Gupta V; Dube A; Kakkar S; Sharma S; Keswani P; Agrawal A; Tak A; Nawal CL
    J Assoc Physicians India; 2020 Jun; 68(6):13-19. PubMed ID: 32610873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Arbidol combined with the Chinese medicine Lianhuaqingwen capsule versus arbidol alone in the treatment of COVID-19.
    Liu L; Shi F; Tu P; Chen C; Zhang M; Li X; Li C
    Medicine (Baltimore); 2021 Jan; 100(4):e24475. PubMed ID: 33530261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and safety analysis of SanHanHuaShi granules for the treatment of coronavirus disease 2019: Study protocol and statistical analysis plan for a randomized, parallel-controlled, open-label clinical trial.
    Liu Y; Chen X; Wang H; Yao C; Gou X; Gao Z; Sun L; Liu D; Tang C; Wei Y; Ding Q; Yang H; Lin J; Chen K; Chen J; Zhao L; Li M; Han L; Wang J; Ren J; Zhang Y
    Front Pharmacol; 2022; 13():936925. PubMed ID: 36052134
    [No Abstract]   [Full Text] [Related]  

  • 9. Favipiravir Versus Arbidol for Clinical Recovery Rate in Moderate and Severe Adult COVID-19 Patients: A Prospective, Multicenter, Open-Label, Randomized Controlled Clinical Trial.
    Chen C; Zhang Y; Huang J; Yin P; Cheng Z; Wu J; Chen S; Zhang Y; Chen B; Lu M; Luo Y; Ju L; Zhang J; Wang X
    Front Pharmacol; 2021; 12():683296. PubMed ID: 34539392
    [No Abstract]   [Full Text] [Related]  

  • 10. Safety of SARS-CoV2 vaccination and COVID-19 short-term outcome in pediatric acquired demyelinating disorders of central nervous system: A single center experience.
    Monte G; Papetti L; Ferilli MAN; Ursitti F; Moavero R; Sforza G; Panella E; Tarantino S; Checchi MP; Vigevano F; Palma P; Valeriani M
    Front Immunol; 2023; 14():1106472. PubMed ID: 36761740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-inflammatory response of cardamom extract and prediction of therapeutic window in COVID-19 patients by assessing inflammatory markers using RT-PCR.
    Shakeeb N; Varkey P; Hynse A; Mandlecha A
    Inflammopharmacology; 2022 Jun; 30(3):883-894. PubMed ID: 35320494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19.
    Zhu Z; Lu Z; Xu T; Chen C; Yang G; Zha T; Lu J; Xue Y
    J Infect; 2020 Jul; 81(1):e21-e23. PubMed ID: 32283143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A trial of arbidol hydrochloride in adults with COVID-19.
    Zhao J; Zhang J; Jin Y; Tang Z; Hu K; Sun H; Shi M; Yang Q; Gu P; Guo H; Li Q; Zhang H; Li C; Yang M; Xiong N; Dong X; Xu J; Lin F; Wang T; Yang C; Huang B; Zhang J; Chen S; He Q; Zhou M; Qu J
    Chin Med J (Engl); 2022 Jul; 135(13):1531-8. PubMed ID: 35830201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Lopinavir/Ritonavir or Arbidol in Adult Patients with Mild/Moderate COVID-19: An Exploratory Randomized Controlled Trial.
    Li Y; Xie Z; Lin W; Cai W; Wen C; Guan Y; Mo X; Wang J; Wang Y; Peng P; Chen X; Hong W; Xiao G; Liu J; Zhang L; Hu F; Li F; Zhang F; Deng X; Li L
    Med; 2020 Dec; 1(1):105-113.e4. PubMed ID: 32838353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Traditional Chinese Medicine, Maxingshigan-Weijing in the management of COVID-19 patients with severe acute respiratory syndrome: A structured summary of a study protocol for a randomized controlled trial.
    Zeng C; Yuan Z; Pan X; Zhang J; Zhu J; Zhou F; Shan Z; Yuan Y; Ye R; Cheng J
    Trials; 2020 Dec; 21(1):1029. PubMed ID: 33357239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multi-center, randomized controlled trial by the Integrative Management in Japan for Epidemic Disease (IMJEDI study-RCT) on the use of Kampo medicine, kakkonto with shosaikotokakikyosekko, in mild-to-moderate COVID-19 patients for symptomatic relief and prevention of severe stage: a structured summary of a study protocol for a randomized controlled trial.
    Takayama S; Namiki T; Ito T; Arita R; Nakae H; Kobayashi S; Yoshino T; Ishigami T; Tanaka K; Kainuma M; Nochioka K; Takagi A; Mimura M; Yamaguchi T; Ishii T
    Trials; 2020 Oct; 21(1):827. PubMed ID: 33008479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beneficial effect of Arbidol in the management of COVID-19 infection.
    Jie X; Hongmei Y; Ping F; Kuikui Z; Bohan Y; Rui M
    Aging (Albany NY); 2021 Apr; 13(7):9253-9264. PubMed ID: 33811756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential of Arbidol for Post-exposure Prophylaxis of COVID-19 Transmission: A Preliminary Report of a Retrospective Cohort Study.
    Zhang JN; Wang WJ; Peng B; Peng W; Zhang YS; Wang YL; Wan Y; Chang J; Mao L; Miao XP; Li YN; Zhou YF; Hu B
    Curr Med Sci; 2020 Jun; 40(3):480-485. PubMed ID: 32474860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of Lianhuaqingwen for mild or moderate coronavirus disease 2019: A meta-analysis of randomized controlled trials.
    Fan Z; Guo G; Che X; Yang Y; Liu Y; Li L; Chang X; Han L; Cai X; Tang H
    Medicine (Baltimore); 2021 May; 100(21):e26059. PubMed ID: 34032734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical evaluation of Shufeng Jiedu Capsules combined with umifenovir (Arbidol) in the treatment of common-type COVID-19: a retrospective study.
    Chen J; Lin S; Niu C; Xiao Q
    Expert Rev Respir Med; 2021 Feb; 15(2):257-265. PubMed ID: 32941741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.